Chemoradiotherapy with Paclitaxel Liposome Plus Cisplatin for Locally Advanced Esophageal Squamous Cell Carcinoma: A Retrospective Analysis

Overview

Journal Cancer Med

Specialty Oncology

Date 2023 Apr 4

PMID 37012831

Authors

Qiong Yi

Canyu Liu

Yingshan Cui

Yanguang Yang

Yaqi Li

Xingwen Fan

Kailiang Wu

Affiliations

Soon will be listed here.

Abstract

Purpose: This single-center retrospective clinical study aimed to evaluate the efficacy and feasibility of chemoradiotherapy with paclitaxel liposome plus cisplatin for locally advanced esophageal squamous cell carcinoma (ESCC).

Methods: Patients with locally advanced ESCC treated with paclitaxel-liposome-based chemoradiotherapy between 2016 and 2019 were retrospectively analyzed. Overall survival (OS) and progression-free survival (PFS) were evaluated using Kaplan-Meier analysis.

Results: Thirty-nine patients with locally advanced ESCC were included in this study. The median follow-up time was 31.5 months. The median OS time was 38.3 (95% confidence interval [CI]: 32.1-45.1) months, and the 1-, 2-, and 3-year OS rates were 84.6%, 64.1%, and 56.2%, respectively. The median PFS time was 32.1 (95% CI: 25.4-39.0) months, and the 1-, 2-, and 3-year PFS rates were 71.8%, 43.6%, and 43.6%, respectively. The most common Grade IV toxicity was neutropenia (30.8%) followed by lymphopenia (20.5%). There were no cases of Grade III/IV radiation pneumonia, and four patients (10.3%) had Grade III/IV esophagitis.

Conclusion: Chemoradiotherapy using paclitaxel liposome and cisplatin is a well-tolerated and effective treatment regimen for locally advanced ESCC.

Citing Articles

Nanodrugs systems for therapy and diagnosis of esophageal cancer.

Zhang L, Li X, Yue G, Guo L, Hu Y, Cui Q Front Bioeng Biotechnol. 2023; 11:1233476.

PMID: 37520291 PMC: 10373894. DOI: 10.3389/fbioe.2023.1233476.

Irritability and risk of lung cancer: a Mendelian randomization and mediation analysis.

Qi A, Jiao L, Zhang Y, Zhou H, He Y, Gong Y J Cancer Res Clin Oncol. 2023; 149(11):8649-8654.

PMID: 37103569 DOI: 10.1007/s00432-023-04791-2.

Chemoradiotherapy with paclitaxel liposome plus cisplatin for locally advanced esophageal squamous cell carcinoma: A retrospective analysis.

Yi Q, Liu C, Cui Y, Yang Y, Li Y, Fan X Cancer Med. 2023; 12(6):6477-6487.

PMID: 37012831 PMC: 10067117. DOI: 10.1002/cam4.5416.

References

Zhou H, Yan J, Chen W, Yang J, Liu M, Zhang Y . Population Pharmacokinetics and Exposure-Safety Relationship of Paclitaxel Liposome in Patients With Non-small Cell Lung Cancer. Front Oncol. 2021; 10:1731. PMC: 7892953. DOI: 10.3389/fonc.2020.01731. View

Zhu H, Ai D, Tang H, Badakhshi H, Fan J, Deng J . Long-term results of paclitaxel plus cisplatin with concurrent radiotherapy for loco-regional esophageal squamous cell carcinoma. World J Gastroenterol. 2017; 23(3):540-546. PMC: 5291860. DOI: 10.3748/wjg.v23.i3.540. View

Qiu B, Wang D, Yang H, Xie W, Liang Y, Cai P . Combined modalities of magnetic resonance imaging, endoscopy and computed tomography in the evaluation of tumor responses to definitive chemoradiotherapy in esophageal squamous cell carcinoma. Radiother Oncol. 2016; 121(2):239-245. DOI: 10.1016/j.radonc.2016.09.017. View

Crosby T, Hurt C, Falk S, Gollins S, Mukherjee S, Staffurth J . Chemoradiotherapy with or without cetuximab in patients with oesophageal cancer (SCOPE1): a multicentre, phase 2/3 randomised trial. Lancet Oncol. 2013; 14(7):627-37. DOI: 10.1016/S1470-2045(13)70136-0. View

Sung H, Ferlay J, Siegel R, Laversanne M, Soerjomataram I, Jemal A . Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries. CA Cancer J Clin. 2021; 71(3):209-249. DOI: 10.3322/caac.21660. View

Lin S, Wang L, Myles B, Thall P, Hofstetter W, Swisher S . Propensity score-based comparison of long-term outcomes with 3-dimensional conformal radiotherapy vs intensity-modulated radiotherapy for esophageal cancer. Int J Radiat Oncol Biol Phys. 2012; 84(5):1078-85. PMC: 3923623. DOI: 10.1016/j.ijrobp.2012.02.015. View

Conroy T, Galais M, Raoul J, Bouche O, Gourgou-Bourgade S, Douillard J . Definitive chemoradiotherapy with FOLFOX versus fluorouracil and cisplatin in patients with oesophageal cancer (PRODIGE5/ACCORD17): final results of a randomised, phase 2/3 trial. Lancet Oncol. 2014; 15(3):305-14. DOI: 10.1016/S1470-2045(14)70028-2. View

Alushin G, Lander G, Kellogg E, Zhang R, Baker D, Nogales E . High-resolution microtubule structures reveal the structural transitions in αβ-tubulin upon GTP hydrolysis. Cell. 2014; 157(5):1117-29. PMC: 4054694. DOI: 10.1016/j.cell.2014.03.053. View

Ajani J, Ilson D, Daugherty K, Pazdur R, Lynch P, Kelsen D . Activity of taxol in patients with squamous cell carcinoma and adenocarcinoma of the esophagus. J Natl Cancer Inst. 1994; 86(14):1086-91. DOI: 10.1093/jnci/86.14.1086. View

10.

Zeng J, Cui X, Cheng L, Chen Y, Du X, Sheng L . Liposome-paclitaxel and carboplatin combination chemoradiotherapy for patients with locally advanced esophageal squamous cell carcinoma. Cancer Radiother. 2021; 25(5):441-446. DOI: 10.1016/j.canrad.2021.01.008. View

11.

Zeng S, Li L, Zhong M, Jiang W, Wu Y, Liu Y . [A randomized controlled trial of two chemotherapy regimens (paclitaxel liposome combined with platinum and paclitaxel combined with platinum) in concurrent chemoradiotherapy for cervical carcinoma]. Zhonghua Zhong Liu Za Zhi. 2011; 33(7):517-9. View

12.

Liu S, Sun X, Li X, Chen Q, Lin H, Wen Y . Liposomal paclitaxel versus docetaxel in induction chemotherapy using Taxanes, cisplatin and 5-fluorouracil for locally advanced nasopharyngeal carcinoma. BMC Cancer. 2018; 18(1):1279. PMC: 6302514. DOI: 10.1186/s12885-018-5192-x. View

13.

Xu X, Sun Z, Wu H, Zhang C, Hu B, Rong L . Diffusion-weighted MRI and F-FDG PET/CT in assessing the response to neoadjuvant chemoradiotherapy in locally advanced esophageal squamous cell carcinoma. Radiat Oncol. 2021; 16(1):132. PMC: 8287821. DOI: 10.1186/s13014-021-01852-z. View

14.

Li B, Liu Y, Peng J, Sun C, Rang W . Trends of Esophageal Cancer Incidence and Mortality and Its Influencing Factors in China. Risk Manag Healthc Policy. 2021; 14:4809-4821. PMC: 8643221. DOI: 10.2147/RMHP.S312790. View

15.

Herskovic A, Martz K, Al-Sarraf M, Leichman L, Brindle J, Vaitkevicius V . Combined chemotherapy and radiotherapy compared with radiotherapy alone in patients with cancer of the esophagus. N Engl J Med. 1992; 326(24):1593-8. DOI: 10.1056/NEJM199206113262403. View

16.

Eisenhauer E, Therasse P, Bogaerts J, Schwartz L, Sargent D, Ford R . New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). Eur J Cancer. 2008; 45(2):228-47. DOI: 10.1016/j.ejca.2008.10.026. View

17.

Fang P, Musall B, Son J, Moreno A, Hobbs B, Carter B . Multimodal Imaging of Pathologic Response to Chemoradiation in Esophageal Cancer. Int J Radiat Oncol Biol Phys. 2018; 102(4):996-1001. PMC: 6119639. DOI: 10.1016/j.ijrobp.2018.02.029. View

18.

Ye L, He J, Hu Z, Dong Q, Wang H, Fu F . Antitumor effect and toxicity of Lipusu in rat ovarian cancer xenografts. Food Chem Toxicol. 2012; 52:200-6. DOI: 10.1016/j.fct.2012.11.004. View

19.

Liang J, Bi N, Wu S, Chen M, Lv C, Zhao L . Etoposide and cisplatin versus paclitaxel and carboplatin with concurrent thoracic radiotherapy in unresectable stage III non-small cell lung cancer: a multicenter randomized phase III trial. Ann Oncol. 2017; 28(4):777-783. DOI: 10.1093/annonc/mdx009. View

20.

Sharma A, Mayhew E, Bolcsak L, Cavanaugh C, Harmon P, Janoff A . Activity of paclitaxel liposome formulations against human ovarian tumor xenografts. Int J Cancer. 1997; 71(1):103-7. DOI: 10.1002/(sici)1097-0215(19970328)71:1<103::aid-ijc17>3.0.co;2-j. View